Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28722165 | 1.00 | F2RL1 (0.40) | F2RL1ADRB1ADRB2CYP2D6NFKB1 | |
| SCHEMBL24631038 | 1.00 | F2RL1 (0.40) | F2RL1ADRB1ADRB2CYP2D6NFKB1 | |
| SCHEMBL28724403 | 0.86 | F2RL1 (0.43) | F2RL1DGAT1 | |
| SCHEMBL29594153 | 0.86 | F2RL1 (0.43) | F2RL1DGAT1 | |
| SCHEMBL24631037 | 0.86 | F2RL1 (0.43) | F2RL1DGAT1 | |
| SCHEMBL1957623 | 0.76 | F2RL1 (0.39) | F2RL1DGAT1 | |
| SCHEMBL28722129 | 0.76 | F2RL1 (0.39) | F2RL1 | |
| SCHEMBL22864283 | 0.75 | ADRB2 (0.35) | F2RL1ADRB1ADRB2CYP2D6NFKB1 | |
| SCHEMBL22864153 | 0.74 | DGAT1 (0.39) | F2RL1DGAT1 | |
| SCHEMBL29593705 | 0.74 | DGAT1 (0.39) | F2RL1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3993878-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | Curasen Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114340740-A | Beta adrenergic agonists and methods of use thereof | 库拉森疗法公司 | 2022-04-12 | — | — | CN | disclosed |